https://scholars.lib.ntu.edu.tw/handle/123456789/477730
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Piccart-Gebhart M. | en_US |
dc.contributor.author | Holmes E. | en_US |
dc.contributor.author | Baselga J. | en_US |
dc.contributor.author | De Azambuja E. | en_US |
dc.contributor.author | Dueck A.C. | en_US |
dc.contributor.author | Viale G. | en_US |
dc.contributor.author | Zujewski J.A. | en_US |
dc.contributor.author | Goldhirsch A. | en_US |
dc.contributor.author | Armour A. | en_US |
dc.contributor.author | Pritchard K.I. | en_US |
dc.contributor.author | McCullough A.E. | en_US |
dc.contributor.author | Dolci S. | en_US |
dc.contributor.author | McFadden E. | en_US |
dc.contributor.author | Holmes A.P. | en_US |
dc.contributor.author | Tonghua L. | en_US |
dc.contributor.author | Eidtmann H. | en_US |
dc.contributor.author | Dinh P. | en_US |
dc.contributor.author | Di Cosimo S. | en_US |
dc.contributor.author | Harbeck N. | en_US |
dc.contributor.author | Tjulandin S. | en_US |
dc.contributor.author | Im Y.-H. | en_US |
dc.contributor.author | CHIUN-SHENG HUANG | en_US |
dc.contributor.author | Diéras V. | en_US |
dc.contributor.author | Hillman D.W. | en_US |
dc.contributor.author | Wolff A.C. | en_US |
dc.contributor.author | Jackisch C. | en_US |
dc.contributor.author | Lang I. | en_US |
dc.contributor.author | Untch M. | en_US |
dc.contributor.author | Smith I. | en_US |
dc.contributor.author | Boyle F. | en_US |
dc.contributor.author | Xu B. | en_US |
dc.contributor.author | Gomez H. | en_US |
dc.contributor.author | Suter T. | en_US |
dc.contributor.author | Gelber R.D. | en_US |
dc.contributor.author | Perez E.A. | en_US |
dc.creator | Piccart-Gebhart M.;Holmes E.;Baselga J.;De Azambuja E.;Dueck A.C.;Viale G.;Zujewski J.A.;Goldhirsch A.;Armour A.;Pritchard K.I.;Mccullough A.E.;Dolci S.;Mcfadden E.;Holmes A.P.;Tonghua L.;Eidtmann H.;Dinh P.;Di Cosimo S.;Harbeck N.;Tjulandin S.;Im Y.-H.;Chiun-Sheng Huang;D?Eras V.;Hillman D.W.;Wolff A.C.;Jackisch C.;Lang I.;Untch M.;Smith I.;Boyle F.;Xu B.;Gomez H.;Suter T.;Gelber R.D.;Perez E.A. | - |
dc.date.accessioned | 2020-03-23T07:19:02Z | - |
dc.date.available | 2020-03-23T07:19:02Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84963612956&doi=10.1200%2fJCO.2015.62.1797&partnerID=40&md5=f5d59ae82e311182f1e74c010f8c4d63 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/477730 | - |
dc.description.abstract | Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2-positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed human epidermal growth factor 2-positive early breast cancer were randomly assigned to 1 year of adjuvant therapy with T, L, their sequence (T→L), or their combination (L+T). The primary end point was disease-free survival (DFS), with 850 events required for 80% power to detect a hazard ratio (HR) of 0.8 for L+T versus T. Results Between June 2007 and July 2011, 8,381 patients were enrolled. In 2011, due to futility to demonstrate noninferiority of L versus T, the L arm was closed, and patients free of disease were offered adjuvant T. A protocol modification required P # .025 for the two remaining pairwise comparisons. At a protocol-specified analysis with a median follow-up of 4.5 years, a 16% reduction in the DFS hazard rate was observed with L+T compared with T (555 DFS events; HR, 0.84; 97.5% CI, 0.70 to 1.02; P = .048), and a 4%reduction was observed with T→L compared with T (HR, 0.96; 97.5%CI, 0.80 to 1.15; P = .61). L-treated patients experienced more diarrhea, cutaneous rash, and hepatic toxicity compared with T-treated patients. The incidence of cardiac toxicity was low in all treatment arms. Conclusion Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity. One year of adjuvant T remains standard of care. ?2015 by American Society of Clinical Oncology. | en_US |
dc.publisher | American Society of Clinical Oncology | en_US |
dc.relation.ispartof | Journal of Clinical Oncology | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | carboplatin; docetaxel; lapatinib; paclitaxel; trastuzumab; antineoplastic agent; epidermal growth factor receptor 2; ERBB2 protein, human; lapatinib; quinazoline derivative; trastuzumab; tumor marker; adult; aged; Article; breast cancer; cancer adjuvant therapy; cardiotoxicity; clinical protocol; controlled study; diarrhea; disease free survival; drug fatality; drug safety; drug withdrawal; epidermal growth factor receptor 2 positive breast cancer; epidermal growth factor receptor 2 positive breast cancer; febrile neutropenia; female; hepatobiliary disease; human; incidence; interstitial pneumonia; liver toxicity; loading drug dose; major clinical study; multicenter study; multiple cycle treatment; neutropenia; phase 3 clinical trial; priority journal; randomized controlled trial; rash; skin toxicity; treatment outcome; treatment response; adjuvant chemotherapy; Breast Neoplasms; cancer staging; chemistry; clinical trial; drug administration; follow up; Kaplan Meier method; middle aged; pathology; patient selection; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Patient Selection; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | - |
dc.title | Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1200/JCO.2015.62.1797 | - |
dc.identifier.pmid | 26598744 | - |
dc.identifier.scopus | 2-s2.0-84963612956 | - |
dc.relation.pages | 1034-1042 | en_US |
dc.relation.journalvolume | 34 | en_US |
dc.relation.journalissue | 10 | en_US |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.orcid | 0000-0002-6557-211X | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。